BioPoint Inc

01/16/2026

AbbVie’s Skyrizi was the top TV drug ad spender for the full year again, leading annual pharmaceutical TV ad spending with hundreds of millions invested. Johnson & Johnson’s Tremfya was a close challenger, frequently trading monthly spots but finishing just behind Skyrizi in total spend. https://www.fiercepharma.com/marketing/abbvies-skyrizi-takes-full-year-tv-ad-spending-crown-yet-again-jjs-tremfya-hot-pursuit

For the fourth year running—and the third in a row for | For the fourth year running—and the third in a row for Skyrizi specifically—an AbbVie immunology med has claimed the top spot in the full-year TV drug ad spending rankings.

01/15/2026

The FDA has asked Novo Nordisk and Eli Lilly to remove suicide-related warnings from their GLP-1 weight-loss drug labels after a review found no evidence these medications increase risk of suicidal thoughts or behavior. https://www.biospace.com/fda/fda-asks-novo-lilly-to-remove-suicide-warnings-from-glp-1-weight-loss-products

A more detailed review of data by the FDA showed that GLP-1 drugs do not increase the risk of suicidal ideation or behavior.

01/14/2026

Johnson & Johnson plans to build a new drug manufacturing plant in Wilson, North Carolina, that will create about 500 new jobs as part of its broader investment to expand U.S. pharmaceutical production. https://www.biospace.com/business/j-j-to-add-500-jobs-at-new-plant-doubling-down-on-north-carolina

Johnson & Johnson’s second facility in Wilson, North Carolina, is part of a $55 billion push to make all advanced medicines used in the U.S. domestically.

01/13/2026

Merck and Daiichi Sankyo’s Phase 3 trial of their antibody-drug conjugate ifinatamab deruxtecan was placed on partial clinical hold after an unexpectedly high number of patient deaths linked to lung toxicity were reported. The FDA’s action pauses new enrollment while the companies and regulators review the safety data. https://www.biospace.com/drug-development/patient-deaths-put-merck-daiichi-sankyos-antibody-drug-conjugate-on-hold

The FDA initially placed the Phase III IDeate-Lung02 study on hold due to a “higher than expected” number of deaths in patients treated with ifinatamab deruxtecan.

01/12/2026

Biopharma is heading into 2026 with renewed momentum, driven by strong clinical data in rare disease, cancer, and neuroscience. Key upcoming trial readouts are fueling optimism after recent industry challenges. https://www.biospace.com/drug-development/biopharma-momentum-to-propel-rare-disease-cancer-neuro-forward-in-2026

After years stuck in the “doldrums,” the biopharma sector is in a “very good place” heading into the new year, analysts told BioSpace, with both rare and chronic diseases headlining investor and R&D interest as JPM26 kicks off.

01/09/2026

GSK and Ionis reported late-stage trial results showing their hepatitis B drug bepirovirsen achieved a functional cure in some patients. The data position the therapy for potential FDA filings in 2026. https://www.biospace.com/drug-development/gsk-ionis-achieve-functional-cure-in-hepatitis-b-studies-clearing-path-for-fda-run

Though specific data for bepirovirsen remain under wraps, GSK plans to file for approval in the first quarter of 2026.

01/08/2026

The FDA has again rejected Vanda’s bid to expand Hetlioz for treating jet lag disorder, and the company’s shares slid about 11% on the news. Vanda disputes the decision and says it will keep pushing for approval and next steps. https://www.fiercepharma.com/pharma/vandas-shares-down-11-after-2nd-fda-rejection-hetlioz-jet-lag-disorder

In a saga that has spread over seven years, the FDA has again

01/06/2026

Huntington’s disease drug development is at a turning point, with encouraging gene therapy data offering new hope after years of setbacks. However, regulatory hurdles and mixed trial results show that a clear path to approval is still uncertain. https://www.biospace.com/drug-development/deep-dive-huntingtons-at-a-crossroads

Recent breakthroughs and three decades of progress in treating Huntington's disease

01/05/2026

Eli Lilly is targeting $94.3 billion in annual revenue by 2027, with 2026’s launch of its oral obesity drug orforglipron and other pipeline milestones seen as key drivers in a heated battle with Novo Nordisk. https://www.biospace.com/business/lillys-path-to-94b-in-revenue-rests-on-oral-obesity-market-and-other-2026-milestones

The fierce rivalry between Novo Nordisk and Eli Lilly is alive and well, as the two companies are expected to face off with their new obesity pills this year.

12/23/2025

We wish you a season of peace, joy, and connection. May your holidays be bright, your rest well-earned, and your new year full of possibility.

12/19/2025

Novo Nordisk has submitted a New Drug Application to the FDA for CagriSema, a once-weekly injectable obesity treatment that combines an amylin analogue with semaglutide to target weight management. https://www.biospace.com/fda/novo-nordisk-files-combo-obesity-drug-cagrisema-for-fda-approval

The filing comes as Novo fights tooth-and-nail with rival Lilly to regain its footing at the top of the weight loss market.

12/17/2025

Big pharmaceutical companies including AbbVie, Eli Lilly, J&J and Merck are urging the FDA to separate facility inspections from the drug approval review process so inspections can happen earlier and reduce delays or complete response letters tied to manufacturing issues. https://www.biospace.com/fda/big-pharma-pushes-fda-to-decouple-inspections-from-drug-approval-applications

Representatives of companies including AbbVie, Eli Lilly, Johnson & Johnson and Merck have voiced concerns about the FDA’s approach to pre-approval inspections.